What's in Shao-quan Zhang's pipeline?

Shao-quan Zhang has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Shao-quan Zhang's portfolio?

Top competitors by shared drug class: ANRS, Emerging Infectious Diseases.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shao-quan-zhang.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shao-quan Zhang — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shao-quan Zhang pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Telbivudine, Lamivudine, Adefovir ,Enecavir	Telbivudine, Lamivudine, Adefovir ,Enecavir	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase	Virology/Hepatology

Therapeutic area mix

Virology/Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shao-quan Zhang:

Cite this brief

Drug Landscape (2026). Shao-quan Zhang — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shao-quan-zhang. Accessed 2026-05-16.